Prospects For Development Of Vaccines Research Articles

Vaccination against Lucilia cuprina: The causative agent of sheep blowfly strike

The sheep blowfly, Lucilia cuprina, is responsible for over 80% of cases of blowfly strike in Australia and the losses in production and sheep deaths due to flystrike exceed $200 million per annum. Traditional methods of control are becoming less effective because of the blowfly's resistance to insecticides and thus other methods of control are necessary. In general, sheep develop very little immunity to flystrike even after repeated infestation, however vaccination against L. cuprina has shown considerable potential for controlling flystrike. The most successful sources of antigens have been the larvae's secreted proteases and several extracts from gut or peritrophic membrane. Immunization with these antigens results in retardation of larval growth and in some cases larval mortality. On sheep immunized with peritrophic membrane extracts, the growth retardation appears to be caused by a blocking of the peritrophic membrane which results in the larvae being starved of nutrients. The prospects for vaccine development and the remaining barriers to be overcome are discussed.

Acquired immunodeficiency syndrome: progress and prospects for vaccine development.

Acquired immunodeficiency syndrome: progress and prospects for vaccine development.

The virology of human immunodeficiency viruses.

This chapter describes in detail the nature and diversity of currently recognised human immunodeficiency viruses (HIVs). It goes on to describe their genomic organisation and relates these to the functional attributes of gene products. The target cells for HIV and the pathogenesis of disease are outlined from a virological viewpoint. The antigenicity of different viral proteins are reviewed and related to the significance of antibody responses. Finally, this chapter considers the limitations of current animal models and the prospects for vaccine development.

Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development

The protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 was tested in an infant rat infection model. Four monoclonal antibodies to class 1 protein had bactericidal titres exceeding 20000 and they protected infant rats completely against bacterial challenge with meningococci carrying the same class 1 protein, P1.16. One monoclonal antibody to class 3 protein was highly bactericidal (titer > 20 000), whereas two others had no bactericidal activity. All these antibodies gave some protection from infection, resulting in mortalities varying from 66 to 83% as compared to 100% in control rats who had received either unrelated monoclonal antibody or saline. These results strongly speak for class 1 outer membrane protein as a vaccine candidate for meningococcus group B.

The design of new vaccines

The prospects for vaccine development have been transformed by the advent of hybridoma technology for the production of specific monoclonal antibodies and recombinant DNA technology which permits the in vitro expression of genes coding for protective antigens of pathogenic organisms. These techniques are leading to the refinement of existing vaccines and the production of new vaccines against organisms which either cannot be cultured in vitro at all, e.g. hepatitis-B, or can be cultured only on a limited scale, e.g. plasmodial species. The techniques allow for the novel production of both live and dead vaccines. New live vaccines are produced using either site-directed mutagenesis or insertion of genes into hosts such as vaccinia virus, which is a potential carrier of polyvalent vaccines. New subunit vaccines are produced by expression of appropriate genes in E. coli, yeast cells or mammalian cell lines and some, e.g. hepatitis-B surface antigen (HBsAg) are at an advanced stage of development. Recombinant subunit vaccines are also being produced against the sporozoite and blood stages of malaria. Problems, in regard to the development of malaria vaccines, concern the antigenic plasticity of plasmodia and the need to induce both antibody and cell-mediated immunity; nevertheless, the work shows considerable promise of success.